XML 25 R15.htm IDEA: XBRL DOCUMENT
v3.21.1

Stock Plans | 3 Months Ended
--- | ---
Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
Stock Plans | NOTE 9. STOCK PLANS Stock-Based Compensation During the three months ended March 31, 2021, the Company granted options to purchase an aggregate of 92,000 shares of its common stock that are subject to time-based vesting conditions. The Company valued these stock options using the Black-Scholes Merton option pricing model. The following assumptions were used to compute the grant date fair values of the stock options granted during the three months ended March 31, 2021:
Expected term (in years) |  |  | 6.1 |
Expected volatility |  |  | 83 | %
Risk-free interest rate |  |  | 0.6 | %
Expected dividend yield |  |  | — |
The assumptions used in calculating the fair values of purchase rights granted under the ESPP during the three months ended March 31, 2021 are set forth in the table below:
Expected term (in years) |  | 0.5 - 2.0 |
Expected volatility |  | 101% - 119% |
Risk-free interest rate |  |  | 0.1 | %
Expected dividend yield |  |  | — |
The Company’s stock-based compensation expense by type of award and by operating expense grouping are presented below:
|  | Three months ended |
|  | March 31, |
|  | 2021 |  |  | 2020 |
Stock-based compensation expense by type of award: |  |  |  |  |  |  |  |
Restricted stock units |  | $ | 4,171 |  |  | $ | 142 |
Stock awards |  |  | 19 |  |  |  | 62 |
Performance-based stock options |  |  | 16,314 |  |  |  | 1,968 |
Stock options |  |  | 837 |  |  |  | 2,149 |
Employee stock purchase plan |  |  | 150 |  |  |  | 135 |
Common stock issued for services |  |  | 119 |  |  |  | - |
Total |  | $ | 21,610 |  |  | $ | 4,456 |
Stock-based compensation expense by operating expense grouping: |  |  |  |  |  |  |  |
Sales and marketing |  | $ | 898 |  |  | $ | 178 |
Research and development |  |  | 1,019 |  |  |  | 237 |
General and administrative |  |  | 19,693 |  |  |  | 4,041 |
|  | $ | 21,610 |  |  | $ | 4,456 |
Equity Award Activity Under Stock Plans Stock Awards The Company’s stock award activity for the three months ended March 31, 2021 was as follows:
|  |  |  |  |  | Weighted |
|  |  |  |  |  | Average Grant |
|  | Shares |  |  | Date Fair Value |
Unvested at December 31, 2020 |  |  | - |  |  | $ | - |
Granted |  |  | 581 |  |  | $ | 32.33 |
Vested |  |  | (581 | ) |  | $ | 32.33 |
Unvested at March 31, 2021 |  |  | - |  |  |  |  |
All stock awards granted during the three months ended March 31, 2021 were fully vested upon grant. As of March 31, 2021, there was no unrecognized compensation cost related to stock awards granted under the Company’s stock plans. Restricted Stock Units The Company’s restricted stock unit activity for the three months ended March 31, 2021 was as follows:
|  |  |  |  |  | Weighted |
|  |  |  |  |  | Average Grant |
|  | Shares |  |  | Date Fair Value |
Unvested at December 31, 2020 |  |  | 829,124 |  |  | $ | 11.53 |
Granted |  |  | 346,645 |  |  | $ | 47.37 |
Forfeited |  |  | (250 | ) |  | $ | 8.81 |
Vested |  |  | (217,899 | ) |  | $ | 4.73 |
Unvested at March 31, 2021 |  |  | 957,620 |  |  | $ | 26.05 |
As of March 31, 2021, total unrecognized compensation cost related to restricted stock units was $16,840, which is expected to be recognized over a weighted average period of 0.9 year. Performance-Based Stock Options The activity during the three months ended March 31, 2021 related to stock options that are subject to performance-based vesting conditions tied to the achievement of stock price goals by the Company was as follows:
|  |  |  |  |  | Weighted-Average |
|  |  |  |  |  |  |  |  |  | Remaining |  | Aggregate |
|  |  |  |  |  | Exercise |  |  | Contractual |  | Intrinsic |
|  | Options |  |  | Price |  |  | Term |  | Value |
Outstanding at December 31, 2020 |  |  | 4,234,020 |  |  | $ | 10.55 |  |  |  |  |  |  |
Exercised |  |  | (221,936 | ) |  | $ | 5.80 |  |  |  |  |  |  |
Forfeited |  |  | (5,895 | ) |  | $ | 6.02 |  |  |  |  |  |  |
Outstanding at March 31, 2021 |  |  | 4,006,189 |  |  | $ | 10.82 |  |  | 7.27 years |  | $ | 52,715 |
Exercisable at March 31, 2021 |  |  | 3,999,532 |  |  | $ | 10.83 |  |  | 7.27 years |  | $ | 52,594 |
During the first quarter of 2021, the Company achieved all of the stock price milestones applicable to substantially all of the performance-based stock options and, as a result, such performance-based stock options vested and all associated unrecognized compensation was accelerated and recognized in full as a one-time expense of $16,268 in the first quarter of 2021. The aggregate intrinsic value of the options exercised during the three months ended March 31, 2021 was $5,815. No options were exercised during the three months ended March 31, 2020. No performance-based stock options were granted during the three months ended March 31, 2021 and 2020, and no performance-based stock options vested during the three months ended March 31, 2020. Stock Options The activity during the three months ended March 31, 2021 related to all other stock options was as follows:
|  |  |  |  |  | Weighted-Average |
|  |  |  |  |  |  |  |  |  | Remaining |  | Aggregate |
|  |  |  |  |  | Exercise |  |  | Contractual |  | Intrinsic |
|  | Options |  |  | Price |  |  | Term |  | Value |
Outstanding at December 31, 2020 |  |  | 5,400,070 |  |  | $ | 12.60 |  |  |  |  |  |  |
Granted |  |  | 92,000 |  |  | $ | 46.74 |  |  |  |  |  |  |
Exercised |  |  | (319,458 | ) |  | $ | 8.82 |  |  |  |  |  |  |
Forfeited |  |  | (33,397 | ) |  | $ | 9.05 |  |  |  |  |  |  |
Expired |  |  | (1,810 | ) |  | $ | 5.46 |  |  |  |  |  |  |
Outstanding at March 31, 2021 |  |  | 5,137,405 |  |  | $ | 13.47 |  |  | 6.77 years |  | $ | 56,355 |
Exercisable at March 31, 2021 |  |  | 4,074,911 |  |  | $ | 13.91 |  |  | 6.28 years |  | $ | 41,038 |
The weighted average grant date fair value of stock options granted during the three months ended March 31, 2021 and 2020 was $32.68 and $1.64 per share, respectively. The aggregate intrinsic value of the stock options exercised during the three months ended March 31, 2021 was $7,848. No stock options were exercised during the three months ended March 31, 2020. The total grant date fair value of stock options vested during the three months ended March 31, 2021 and 2020 was $733 and $2,371, respectively. At March 31, 2021, total unrecognized compensation expense related to stock options was $7,765 and is expected to be recognized over a weighted average period of 3.0 years. The aggregate intrinsic values in the tables above represent the difference between the fair market value of the Company’s common stock and the average option exercise price of in-the-money options, multiplied by the number of such stock options. Employee Stock Purchase Plan During the three months ended March 31, 2021, a total of 67,068 shares of common stock were purchased under the Company’s ESPP. As of March 31, 2021, accrued employee contributions for future purchases under the ESPP totaled $119.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration